Who
Bhaskar Anand
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Summit Therapeutics; SVP, Chief Accounting Officer, Reata Pharmaceuticals.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $554K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Jan 2022
- Last trade
- 8 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 14 Oct 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Jan 2026filed 12 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 8 Jan 2026filed 12 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $500K26,680 at $18.74 | filing |
| 18 Sep 2025filed 19 Sep 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 | filing |
| 29 Apr 2025filed 1 May 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 | filing |
| 29 Apr 2025filed 1 May 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 | filing |
| 12 Jan 2025filed 14 Jan 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 | filing |
| 11 Sep 2024filed 13 Sep 2024 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $500K22,026 at $22.70 | filing |
| 2 Apr 2024filed 4 Apr 2024 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —23,438 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —33,500 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticals | SEC FORM 4 Code D | —24,089 | filing |
| 5 Sep 2023filed 7 Sep 2023 | Reata Pharmaceuticals | SEC FORM 4 Sold | $69K406 at $169.20 | filing |
| 16 Aug 2023filed 17 Aug 2023 | Reata Pharmaceuticals | SEC FORM 4 Sold | $35K210 at $168.42 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Reata Pharmaceuticals | SEC FORM 4 Sold | $33K193 at $169.06 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —1,562 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Reata Pharmaceuticals | SEC FORM 4 Code M | $43K1,562 at $27.32 | filing |
News
No headline names them, or the companies they trade most, lately.